# US 2012/0252762 A1 · Anti-cancer agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252762 A1
- Document ID: US20120252762A1
- Status: Published application
- Kind: A1
- Application number: 13/513,909
- Filed: 2010-12-20
- Published: 2012-10-04
- Earliest claimed: 2009-12-21
- Assignees: Nippon Chemical Industrial Co., Ltd.
- Inventors: Nobuhiko Oohara; Kazuhiro Nakatsui
- Web page: https://patentgrep.com/patent/US20120252762A1

## CPC

- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 35/00: Antineoplastic agents
- C07F 9/650952: {having the nitrogen atoms in the positions 1 and 4}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The anti-cancer agent of the present invention contains at least one kind of phosphine transition metal complex selected from a group of compounds represented by the following Formulae (1a) to (1d). According to this anti-cancer agent, an anti-cancer agent is provided which has a higher anti-cancer activity and lower toxicity compared to anti-cancer agents in the related art. In Formulae (1a), (1b), (1c), and (1d), R1 and R2 represent a linear or branched alkyl group, and R4 has a higher priority than R2 as ranked according to RS notation. R3 and R4 represent a hydrogen atom or a linear or branched alkyl group. M represents an atom of a transition metal selected from a group consisting of gold, copper, and silver. X− represents an anion.

## Claims

### Claim 1

An anti-cancer agent comprising:
at least one kind of phosphine transition metal complex selected from a group of compounds represented by Formulae (1a) to (1d),
wherein in the Formulae, R1 and R2 represent a linear or branched alkyl group, a cycloalkyl group, a cycloalkyl group having a substituent, an adamantyl group, a phenyl group, or a phenyl group having a substituent that has 1 to 10 carbon atoms; R1 and R2 are different from each other, and R1 has a higher priority than R2 as ranked according to RS notation; R3 and R4 represent a hydrogen atom or a linear or branched alkyl group having 1 to 6 carbon atoms, and may be groups that are the same as or different from each other; R3 and R4 may form a saturated or unsaturated ring by binding to each other, and the saturated or unsaturated ring may have a substituent; M represents an atom of a transition metal selected from a group consisting of gold, copper, and silver; and X− represents an anion.

### Claim 2 (depends on 1)

The anti-cancer agent according to claim 1, further comprising:
at least one kind of phosphine transition metal complex selected from a group of compounds represented by Formulae (2a) to (2c),
wherein in the Formulae, R1, R2, R3, R4, M, and X− have the same definition as described above.

### Claim 3 (depends on 1)

The anti-cancer agent according to claim 1, further comprising:
a phosphine transition metal complex represented by Formula (3),
wherein in the formulae, R1, R2, R3, R4, M, and X− have the same definition as described above.

### Claim 4 (depends on 2)

The anti-cancer agent according to claim 2, further comprising:
a phosphine transition metal complex represented by Formula (3),
wherein in the formulae, R1, R2, R3, R4, M, and X− have the same definition as described above.
